A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Study acronym: CONSTANCE
StatusActive, Not Recruiting
PhasePhase 4
Started

Record status This record was last updated July 31, 2026 (before its estimated October 20, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 15, 2026 to Oct 20, 2026
    • Study completion date: Sep 16, 2027 to Sep 20, 2027
    v18
  2. Study sites revised (67)v17
  3. Re-verified, no change to tracked fieldsv16
  4. Study sites: 68 to 67v15
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 69 to 68
    • Primary completion date: Feb 27, 2027 to Oct 15, 2026
    • Study completion date: Jan 31, 2028 to Sep 16, 2027
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Study sites: 63 to 69v13
  2. Study sites: 49 to 63v12
  3. Study sites: 39 to 49v11
  4. Study sites: 28 to 39v10
  5. Study sites: 17 to 28v9
  6. Study sites: 7 to 17v8
  7. Study sites: 5 to 7
    • Primary completion date: Mar 14, 2027 to Feb 27, 2027
    v7
  8. Study sites: 3 to 5v6
  9. Start date changed from estimate of Apr 11, 2025 to Mar 14, 2025v5
  10. Study sites: 1 to 3v4
  11. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Mar 14, 2025 to Apr 11, 2025
    v3
  12. Primary completion date: Feb 14, 2027 to Mar 14, 2027
    • Study completion date: Feb 14, 2028 to Jan 31, 2028
    • Start date: Feb 14, 2025 to Mar 14, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
369 trials monitored
See 29 trials at risk
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Trial Details
NCT Number NCT06795048
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Neovascular Age-related Macular Degeneration (nAMD)
Enrollment 274 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov